Although the clinical application of tyrosine kinase inhibitors, including gefitinib and erlotinib, have shown a dramatic prolong survival in NSCLC patients with EGFR activating mutations, most patients eventually develop acquired resistance 31. Here, EGFR is linked to non-small cell lung carcinoma.